Drugs / Ganwei
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase not applicable1 trial | ||||||
| — | NCT06244550 | Sep 2021 → Mar 2023 | NAFLD1, fibrotic liver disease | Taipei City Hospital | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT06801509 Comparator | Feb → Nov 2025 overdue | herpes zoster | Sinocelltech Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ganwei | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06244550 ↗ |
| Action | Activate | “Both metformin and Ganwei, health supplements containing a potent inducer of glycine N-methyltransferase (GNMT), have shown great promise for the treatment of MASLD.” PMID 41828627 ↗ Mar 2026 |
| Modality | Traditional medicine (herbal / TCM) | “Ganwei compound herbal extract capsules contain extracts from natural foods such as Schisandra chinensis, Paeonia lactiflora, and Punica granatum.” NCT06244550 ↗ |
| Route | Oral | “This trial aims to assess the impact of orally administering Ganwei compound herbal extract capsules on participants and evaluate its effects on fatty liver, liver fibrosis,...” NCT06244550 ↗ |
| Target | GNMT | “Both metformin and Ganwei, health supplements containing a potent inducer of glycine N-methyltransferase (GNMT), have shown great promise for the treatment of MASLD.” PMID 41828627 ↗ Mar 2026 |